Keane Florence K, Tanguturi Shyam K, Zhu Andrew X, Dawson Laura A, Hong Theodore S
Harvard Radiation Oncology Program, Harvard Medical School, 75 Francis Street, Brigham & Women's Hospital, ASB1 L2, Boston, MA 02215, USA.
Massachusetts General Hospital, Division of Hematology-Oncology, Department of Medicine; 32 Fruit St, Yawkey 7, Boston, MA 02114, USA.
Hepat Oncol. 2015 Apr;2(2):133-146. doi: 10.2217/hep.15.7. Epub 2015 Apr 20.
Many patients with primary hepatic malignancies present with advanced disease that is not suitable for surgical resection, orthotopic liver transplantation, or radiofrequency ablation. Outcomes are particularly dismal in patients with large, unresectable tumors and/or tumor venous thrombosis. Liver-directed radiotherapy, including stereotactic body radiotherapy (SBRT), is able to treat a variety of tumor sizes and tumors with venous involvement and has demonstrated excellent safety and control outcomes. SBRT should be considered a standard option in patients with early-stage hepatocellular carcinoma who are not candidates for surgical resection, orthotopic liver transplantation or radiofrequency ablation. SBRT should be strongly considered in patients with larger tumors and/or tumors with tumor venous thrombosis who have adequate liver function. Radiotherapy should remain a focus of hepatocellular carcinoma research.
许多原发性肝癌患者就诊时已处于晚期,不适于手术切除、原位肝移植或射频消融。对于肿瘤体积大、无法切除和/或伴有肿瘤静脉血栓形成的患者,治疗效果尤其不佳。肝脏定向放疗,包括立体定向体部放疗(SBRT),能够治疗各种大小的肿瘤以及伴有静脉受累的肿瘤,并且已显示出极佳的安全性和控制效果。对于不适合手术切除、原位肝移植或射频消融的早期肝细胞癌患者,应将SBRT视为标准治疗选择。对于肿瘤较大和/或伴有肿瘤静脉血栓形成但肝功能良好的患者,应强烈考虑采用SBRT。放射治疗仍应是肝细胞癌研究的重点。